First Tracks Biotherapeutics, Inc. TRAX
—
34.42
(1.41)
(3.94%)
as of 25 Sep
- Market cap
- $1.3B
- P/E
- —
Follow TRAX
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| (189.47%) | — | — | — | ||
ROIC |
(14,855.88%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(104.29%) | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(4.23) | — | — | 0.00 | |
Free Cash Flow |
(148.24) | — | — | — | |
Capital Expenditures |
(0.12) | — | — | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(43.98%) | 0.00% | 0.00% | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.85 | — | — | — | |
Depreciation/Fixed assets |
(1.48) | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.07 | — | — | — | |
Revenue per Share |
0.00 | — | — | 0.00 | |
Operating CF per Share |
(4.23) | — | — | 0.00 | |
Capex per Share |
0.00 | — | — | 0.00 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates